We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
126
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$4.57M 0.15%
+1,336,412
New +$25.3M
STRO icon
127
CALL
Sutro Biopharma
STRO
$401M
$4.55M 0.15%
+20,000
New +$4.75M
NXTC icon
128
NextCure
NXTC
$16.9M
$4.54M 0.15%
37,829
+21,162
+127% +$3.06M
OVID icon
129
Ovid Therapeutics
OVID
$414M
$4.52M 0.15%
+1,124,872
New +$3.74M
CHAQ.U
130
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.4M 0.15%
400,000
– –
ALLK
131
PUT
DELISTED
Allakos
ALLK
$4.33M 0.15%
+37,700
New +$4.76M
CABA icon
132
Cabaletta Bio
CABA
$437M
$4.32M 0.15%
+389,384
New +$4.76M
OCUL icon
133
CALL
Ocular Therapeutix
OCUL
$1.79B
$4.3M 0.14%
262,100
-50,000
-16% -$963K
PLRX icon
134
Pliant Therapeutics
PLRX
$64.4M
$4.28M 0.14%
+108,700
New +$3.53M
CCCC icon
135
C4 Therapeutics
CCCC
$385M
$4.12M 0.14%
111,500
-40,000
-26% -$1.59M
TBIO
136
PUT
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.12M 0.14%
250,000
+246,400
+6,844% +$5.61M
ALLO icon
137
CALL
Allogene Therapeutics
ALLO
$649M
$4.12M 0.14%
+116,600
New +$3.93M
TCDA
138
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.1M 0.14%
775,294
-83,614
-10% -$525K
IONS icon
139
CALL
Ionis Pharmaceuticals
IONS
$8.6B
$4.05M 0.14%
90,000
-200,000
-69% -$11.2M
RNTX
140
Rein Therapeutics
RNTX
$63.1M
$4M 0.13%
+140,000
New +$4.8M
STSA
141
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$4M 0.13%
+676,294
New +$4.1M
KA
142
DELISTED
Kineta, Inc. Common Stock
KA
$3.97M 0.13%
31,353
+12,422
+66% +$1.68M
STOK icon
143
PUT
Stoke Therapeutics
STOK
$1.8B
$3.96M 0.13%
+102,000
New +$5.81M
KURA icon
144
CALL
Kura Oncology
KURA
$800M
$3.96M 0.13%
140,000
-145,000
-51% -$4.59M
ANAB icon
145
CALL
AnaptysBio
ANAB
$1.58B
$3.92M 0.13%
182,100
– –
IMVT icon
146
PUT
Immunovant
IMVT
$7.93B
$3.9M 0.13%
+242,800
New +$6.4M
CRDF icon
147
PUT
Cardiff Oncology
CRDF
$66.5M
$3.87M 0.13%
417,900
– –
ONCT
148
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$3.83M 0.13%
23,016
-28,500
-55% -$3.77M
DMAC icon
149
DiaMedica Therapeutics
DMAC
$342M
$3.8M 0.13%
415,000
– –
PHAT icon
150
Phathom Pharmaceuticals
PHAT
$708M
$3.76M 0.13%
100,000
– –
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.